Validation of an amino-acid-based radionuclide therapy plus external beam radiotherapy in heterotopic glioblastoma models

Israel, Ina; Blass, G; Reiners, Christoph; Samnick, Samuel

doi:10.1016/j.nucmedbio.2010.12.002

Cited by 10 publications

(7 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While 131 IPA + EBRT was generally well tolerated, outcome was not as favourable as previously observed in animal studies (8,21).…”

Section: Discussionmentioning

confidence: 45%

“…Previous animal studies suggested that the 131 I labelled analogue p-[ 131 I]iodo-L-phenylalanine ( 131 IPA) is an effective therapy in mice and rats bearing primary human glioblastoma xenografts (8,18,21).…”

Section: F a Verburg Et Al: 131 Ipa + Ebrt In Recurrent Glioblastomamentioning

confidence: 99%

“…It is therefore likely that 131 IPA likely also acts as a radiosensitizer for EBRT (8,21) through mechanisms that put tumour cells in a more sensitive phase of the cell cycle (9) and by affecting the repair capacity of radiation-induced double-strand breaks (8).…”

Section: F a Verburg Et Al: 131 Ipa + Ebrt In Recurrent Glioblastomamentioning

confidence: 99%

See 2 more Smart Citations

Patients with recurrent glioblastoma multiforme

Verburg¹,

Sweeney²,

Hänscheid³

et al. 2013

Nuklearmedizin

View full text Add to dashboard Cite

show abstract

“…While 131 IPA + EBRT was generally well tolerated, outcome was not as favourable as previously observed in animal studies (8,21).…”

Section: Discussionmentioning

confidence: 45%

Section: F a Verburg Et Al: 131 Ipa + Ebrt In Recurrent Glioblastomamentioning

confidence: 99%

See 1 more Smart Citation

Patients with recurrent glioblastoma multiforme

Verburg¹,

Sweeney²,

Hänscheid³

et al. 2013

Nuklearmedizin

View full text Add to dashboard Cite

show abstract

“…They concluded that EBRT, used to pretreat bulky sites, may improve clinical outcomes and potentially extend survival when combined with radioimmunotherapy. Furthermore, several preclinical mouse and rat model studies of heterotopic and orthotopic glioblastomas have also found a positive synergistic effect of radionuclide therapy and EBRT [19,20]: by combining both, a stronger reduction in tumor mass was measured than achieved with either treatment modality alone.…”

Section: Discussionmentioning

confidence: 99%

Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma

et al. 2012

Self Cite

View full text Add to dashboard Cite

BackgroundExternal beam radiotherapy (EBRT) is the treatment of choice for irresectable meningioma. Due to the strong expression of somatostatin receptors, peptide receptor radionuclide therapy (PRRT) has been used in advanced cases. We assessed the feasibility and tolerability of a combination of both treatment modalities in advanced symptomatic meningioma.Methods10 patients with irresectable meningioma were treated with PRRT (177Lu-DOTA0,Tyr3 octreotate or - DOTA0,Tyr3 octreotide) followed by external beam radiotherapy (EBRT). EBRT performed after PRRT was continued over 5–6 weeks in IMRT technique (median dose: 53.0 Gy). All patients were assessed morphologically and by positron emission tomography (PET) before therapy and were restaged after 3–6 months. Side effects were evaluated according to CTCAE 4.0.ResultsMedian tumor dose achieved by PRRT was 7.2 Gy. During PRRT and EBRT, no side effects > CTCAE grade 2 were noted. All patients reported stabilization or improvement of tumor-associated symptoms, no morphologic tumor progression was observed in MR-imaging (median follow-up: 13.4 months). The median pre-therapeutic SUVmax in the meningiomas was 14.2 (range: 4.3–68.7). All patients with a second PET after combined PRRT + EBRT showed an increase in SUVmax (median: 37%; range: 15%–46%) to a median value of 23.7 (range: 8.0–119.0; 7 patients) while PET-estimated volume generally decreased to 81 ± 21% of the initial volume.ConclusionsThe combination of PRRT and EBRT is feasible and well tolerated. This approach represents an attractive strategy for the treatment of recurring or progressive symptomatic meningioma, which should be further evaluated.

show abstract

“…The glioma cells were cultured as described previously (Samnick et al, 2009;Israel et al, 2011). In details: T3868 and F98 cells were grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with glucose (4.5 g/L), 10% fetal bovine serum (FBS), L-glutamine (584 mg/L) and 1% penicillin (100 IU/mL)/streptomycin (100 μg/mL) (Life Technologies GmbH, Darmstadt, Germany) and A1207 cells in Royal Park Memorial Institute (RPMI)-1640 medium supplemented with glucose (4.5 g/L), 10% fetal bovine serum (FBS), L-glutamine (300 mg/L) and 1% penicillin (100 IU/mL)/streptomycin (100 μg/mL) (Life Technologies GmbH, Darmstadt, Germany).…”

Section: Cell Lines and Cell Culturementioning

confidence: 99%